ArticleJournal of translational medicine2026
SNX8 regulates BMPR2-mediated SMAD5 proteostasis to drive epithelial-mesenchymal transition in hepatocellular carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is characterized by high metastasis and poor prognosis. While the sorting nexin (SNX) family is linked to tumorigenesis, the role of SNX8 in HCC remains unexplored.
methodsSNX8 expression and prognostic value were validated using TCGA datasets and clinical tissues. The impact of SNX8 on malignant phenotypes was evaluated via in vitro assays and in vivo xenograft models. RNA-seq was conducted to elucidate underlying mechanisms, followed by rescue experiments using pharmacological agents and plasmid transfection to verify key proteins.
resultsSNX8 is significantly overexpressed in HCC and predicts poor patient prognosis. Mechanistically, SNX8 facilitates BMPR2 sorting and trafficking to the cell membrane, enabling SMAD5 phosphorylation and nuclear translocation of the p-SMAD5/SMAD4 complex to activate SNAIL1-mediated Epithelial-mesenchymal transition (EMT). Conversely, SNX8 inhibition causes abnormal intracellular accumulation of BMPR2, leading to the ubiquitin-proteasome degradation of SMAD5 due to its failed recruitment to the receptor. Overexpressing SMAD5 successfully rescues the impaired proliferation and migration induced by SNX8 silencing.
conclusionOur study identifies SNX8 as a novel oncogenic regulator that promotes EMT and metastasis in HCC by stabilizing SMAD5 through the BMPR2 signaling axis. These findings highlight the SNX8/SMAD5 axis as a potential therapeutic target for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.